 Principia Biopharma NASDAQ:PRNBs stock had its buy rating restated by investment analysts at Stifel Nicolaus in a research note issued to investors on Thursday, AnalystRatings.com reports. They presently have a 76.00 price objective on the stock. Stifel Nicolaus price objective would suggest a potential upside of 43.59 from the companys current price. PRNB has been ... 